Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2025

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Search results for

There are 22,040 results that match your search.22,040 results
  • Apple and Samsung were everywhere at the OHIM conference marking 10 years of the Community design this week – not just because everyone in the room seemed to have a smartphone or tablet, but because nearly every session made reference to the litigation between the two companies
  • A study from the University of Melbourne shows that Australia’s most expensive drugs are attached to patents not held by the innovator company
  • Baker & McKenzie in Mexico has recruited Christian Alejandro López-Silva as the head of its pharmaceutical and life sciences practice.
  • One of the highlights of last week’s Fordham IP Conference was the lunchtime speech from US District Judge Jed S Rakoff
  • After more than six years of preparation, India will complete its final accession to the Madrid Protocol on July 8
  • Three firms have done the largest number of cases so far at London’s Patents County Court (PCC): Withers & Rogers, Lupton Fawcett and McDaniel & Co. But with the Court becoming ever more popular, which firms will invest the time and people to build an effective practice?
  • David Case has joined Orrick’s Tokyo office as a partner. He advises Japanese clients in IP litigation and arbitration matters, including discovery issues arising from matters before US courts. He also assists clients in implementing intellectual property and FCPA compliance and due diligence programmes.
  • Old Trafford might still be Old Trafford for now, but from July 1 Manchester United’s training ground will be renamed the Aon Training Complex as part of an eight-year sponsorship deal worth £120 million ($185 million)
  • Everyone knows pharmaceutical companies are under pressure as they edge slowly towards (and off) the patent cliff. But now regulators and judges around the world seem to be turning against them too
  • The Supreme Court’s denial of Novartis’s Glivec patent has prompted dire warnings about patent protection in India, but practitioners say that the decision was just a straightforward application of the law